Javier Cortés, MD, PhD, on Chemotherapy De-escalation in HER2-Positive Early Breast Cancer: Practical Considerations From the PHERGain Trial Results

Posted: Tuesday, August 22, 2023

Javier Cortés, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discusses phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the patients treated with trastuzumab and pertuzumab alone, the 3-year invasive disease–free survival rate was 98.8%, with no distant metastases. But how practical is this approach for institutions that lack the appropriate PET technology?

---